A Look at Sophia Genetics's Upcoming Earnings Report

Sophia Genetics (NASDAQ:SOPH) is preparing to release its quarterly earnings on Tuesday, 2026-03-03. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Sophia Genetics to report an earnings per share (EPS) of $-0.20.

Sophia Genetics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

In the previous earnings release, the company missed EPS by $0.10, leading to a 3.42% drop in the share price the following trading session.

Here's a look at Sophia Genetics's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.20	-0.17	-0.19	-0.15
EPS Actual	-0.30	-0.33	-0.26	-0.23
Price Change %	-3.42	-7.95	0.00	0.32

Market Performance of Sophia Genetics's Stock

Shares of Sophia Genetics were trading at $4.5 as of February 27. Over the last 52-week period, shares are up 47.4%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Delving into Sophia Genetics's Background

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Breaking Down Sophia Genetics's Financial Performance

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Sophia Genetics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 22.77%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Sophia Genetics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -102.87%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Sophia Genetics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -29.15%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Sophia Genetics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.74%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Sophia Genetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.04, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

To track all earnings releases for Sophia Genetics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.